P/E ratio for Aarti Drugs (AARTIDRUGS.NS)
P/E ratio as of April 2024 (TTM): 25.0
According to Aarti Drugs's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 25.0409. At the end of 2022 the company had a P/E ratio of 25.7.
P/E ratio history for Aarti Drugs from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 25.7 | 2.45% |
| 2021 | 25.1 | 10.09% |
| 2020 | 22.8 | 86.75% |
| 2019 | 12.2 | -23.08% |
| 2018 | 15.9 | -16.98% |
| 2017 | 19.1 | 2.87% |
| 2016 | 18.6 | -11.43% |
| 2015 | 21.0 | 63.9% |
| 2014 | 12.8 | 152.42% |
| 2013 | 5.08 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.